NasdaqCM - Delayed Quote USD

Quoin Pharmaceuticals, Ltd. (QNRX)

0.7200

-0.0179

(-2.43%)

At close: 4:00 PM EDT

QNRX: Protocol Modifications Potentially Accelerate, Expand QRX003 Approvals

By M. Marin NASDAQ:QNRX READ THE FULL QNRX RESEARCH REPORT Protocol modifications could accelerate and/or expand QRX003 regulatory approvals … Quoin Pharmaceuticals (NASDAQ:QNRX) has two active Netherton Syndrome (NS) studies that are being conducted concurrently to evaluate lead asset QRX003 for the treatment of NS. Preliminary clinical data was positive. Five of six subjects evaluated had

Zacks Small Cap Research 6 days ago

QNRX
-2.43%
Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2024 Financial Results

FDA clearance to recruit teens in both on-going Netherton Syndrome clinical studies U.S. and International patent filed for novel Netherton Syndrome combination product Cash runway extended into late 2025 ASHBURN, Va., May 09, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on developing and commercializing novel treatments for rare and orphan diseases, today provides a business update and a

GlobeNewswire 19 days ago

QNRX
-2.43%
Quoin Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 9, 2024

ASHBURN, Va., May 02, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company plans to release its first quarter 2024 financial results before the market opens on Thursday, May 9, 2024. The announcement will provide an operational update regarding the company’s achievements during the quarter, and will detail financial highlights. About Qu

GlobeNewswire 26 days ago

QNRX
-2.43%
Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Q4 2023 Earnings Call Transcript

Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Q4 2023 Earnings Call Transcript March 14, 2024 Quoin Pharmaceuticals, Ltd. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day and welcome to the Quoin Pharmaceuticals Fourth Quarter Financial Results and Business Update Conference Call. […]

Insider Monkey 2 months ago

QNRX
-2.43%
Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results

Company reported positive initial clinical data for QRX003 from first six evaluable subjects in ongoing open-label Netherton Syndrome study with positive benefits observed across a number of clinical endpoints Eligibility age for enrollment into both studies has been lowered to fourteen years and older No safety concerns have been observed to date in either ongoing clinical study Quoin expects its cash runway will extend into the second half of 2025 following $6.5 million offering on March 5th C

GlobeNewswire 2 months ago

QNRX
-2.43%
Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ET

ASHBURN, Va., March 07, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company plans to release its fourth quarter and 2023 financial results after the market closes on Wednesday, March 13, 2024. The Company will host a conference call and webcast at 8:30am ET on Thursday, March 14, 2024. The call will include a discussion of fourth quart

GlobeNewswire 2 months ago

QNRX
-2.43%
QNRX: Potential Pool of Study Participants Expands; Financial Position Strengths

By M. Marin NASDAQ:QNRX READ THE FULL QNRX RESEARCH REPORT Strengthening financial position to advance clinical studies… Quoin Pharmaceuticals (NASDAQ:QNRX) has completed a capital raise to strengthen its financial position in order to continue to move lead asset QRX003 and other candidates in its portfolio forward. As Quoin advances clinical studies to evaluate QRX003 for the treatment of

Zacks Small Cap Research 2 months ago

QNRX
-2.43%
Quoin Pharmaceuticals Announces Pricing of $6.5 Million Public Offering

ASHBURN, Va., March 05, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today announced the pricing of its "reasonable best efforts" public offering of 4,062,500 ordinary shares represented by 4,062,500 American Depositary Shares (or pre-funded warrants in lieu thereof), Series D warrants to purchase an aggregate of up to 4,062,500 ordinary shares represented by 4,062,500 Americ

GlobeNewswire 2 months ago

QNRX
-2.43%
Quoin Pharmaceuticals Announces FDA Clearance to Recruit Teen Subjects into Both Ongoing Netherton Syndrome Clinical Studies

Clearance to include teen patients in both the company’s open label and placebo controlled studies expected to significantly expand the number of eligible subjects, potentially expedite recruitment and lead to a more robust data set This important development represents the first ever inclusion of non-adult subjects in Netherton Syndrome clinical studies conducted under an open Investigational New Drug Application ASHBURN, Va., March 04, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDA

GlobeNewswire 2 months ago

QNRX
-2.43%
Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Netherton Syndrome Combination Product

ASHBURN, Va., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company exclusively focused on the development and commercialization of innovative therapies that treat rare and orphan diseases, today announced it has filed U.S. and International patent applications for a novel combination product as a potential treatment of Netherton Syndrome. This new product combines a broad spectrum serine protease inhibitor with

GlobeNewswire 3 months ago

QNRX
-2.43%
Quoin Pharmaceuticals Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton Syndrome

Positive initial data and clean safety profile catalyze optimization planSize of both ongoing clinical trials significantly increasedLower dose eliminated from blinded trialDosing frequency changed to twice-daily from once-daily for both trials ASHBURN, Va., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today announced that it has received U.S. Food and Drug Administr

GlobeNewswire 5 months ago

QNRX
-2.43%
QNRX: Planned Protocol Modifications Might Accelerate QRX003 Regulatory Approval

By M. Marin NASDAQ:QNRX READ THE FULL QNRX RESEARCH REPORT Planned protocol modifications could accelerate & possibly expand regulatory approvals for QRX003 Positive clinical data from the first 6 patients in Quoin Pharmaceuticals’ (NASDAQ:QNRX) QRX003 open-label trial for treatment of Netherton Syndrome (NS) has led to planned protocol amendments, including eliminating the lower 2% dose in

Zacks Small Cap Research 6 months ago

QNRX
-2.43%
Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Q3 2023 Earnings Call Transcript

Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Q3 2023 Earnings Call Transcript November 9, 2023 Operator: Good day, and welcome to the Quoin Pharmaceuticals Third Quarter Fiscal Results and Business Update Conference Call. All participants will be in a listen-only mode. [Operator Instructions] After today’s presentation, there will be an opportunity to ask questions. [Operator Instructions] Please note […]

Insider Monkey 6 months ago

QNRX
-2.43%
Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2023 Financial Results

Company reported positive clinical data for QRX003 from first six evaluable subjects in ongoing open-label Netherton Syndrome study Positive benefits were observed across a number of clinical endpoints including pruritus, Investigator skin scoring system and patient global assessment No safety concerns have been observed to date in either ongoing clinical study Quoin expects its cash runway will extend through the end of 2024 ASHBURN, Va., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals

GlobeNewswire 6 months ago

QNRX
-2.43%
Quoin Pharmaceuticals Announces Third Quarter 2023 Financial Results and Corporate Update Conference Call to be held on Thursday November 9th at 8:30 am ET

ASHBURN, Va., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company plans to release its third quarter 2023 financial results after the market closes on Wednesday, November 8, 2023. The Company will host a conference call and webcast at 8:30am ET on Thursday, November 9, 2023. The call will include a discussion of third quarter

GlobeNewswire 6 months ago

QNRX
-2.43%
REPEAT -- Quoin Pharmaceuticals Announces Additional Positive Clinical Data from Open-Label, Single-Arm Clinical Trial in Netherton Syndrome

Available Clinical Data from Six Subjects Demonstrates Well Defined Efficacy Signals Across a Number of Study Endpoints No Safety Concerns Observed in the Study to Date ASHBURN, Va., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, announces additional positive clinical data from its ongoing open-label study evaluating the safety and efficacy of QRX003 as a potential tre

GlobeNewswire 7 months ago

QNRX
-2.43%
Quoin Pharmaceuticals Announces Additional Positive Clinical Data from Open-Label, Single-Arm Clinical Trial in Netherton Syndrome

Available Clinical Data from Six Subjects Demonstrates Well Define Efficacy Signals Across a Number of Study Endpoints No Safety Concerns Observed in the Study to Date ASHBURN, Va., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, announces additional positive clinical data from its ongoing open-label study evaluating the safety and efficacy of QRX003 as a potential trea

GlobeNewswire 7 months ago

QNRX
-2.43%
QNRX: Positive Early Clinical Data, Moving QRX003 Through Multiple Trials

By M. Marin (NASDAQ:QNRX) READ THE FULL QNRX RESEARCH REPORT Positive early data from clinical studies; open-label study topline data expected in 2H23 Quoin Pharmaceuticals (NASDAQ:QNRX) is advancing clinical studies to evaluate QRX003 for the treatment of Netherton Syndrome (NS) and also developing distribution infrastructure in preparation for the expected commercialization of QRX003 and other

Zacks Small Cap Research 7 months ago

QNRX
-2.43%
Quoin Pharmaceuticals' Commitment to Delivering Treatment for Netherton Syndrome Patients and Creating Value for Shareholders

NEW YORK, NY - (NewMediaWire) - August 09, 2023 - PCG Digital --Quoin Pharmaceuticals (Nasdaq:QNRX), a clinical stage pharmaceutical company specializing in rare and orphan diseases, has achieved significant milestones in its mission to deliver the f...

NewMediaWire 9 months ago

QNRX
-2.43%
Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2023 Financial Results

Company reports positive clinical data for first subject to complete testing in ongoing open-label Netherton Syndrome study Subject’s skin was assessed to be fully clear by Investigator at QRX003 treatment areas Subject also demonstrated key improvements across all other clinical endpoints, including pruritis A majority of patients in both Netherton Syndrome studies are expected to be enrolled by the end of August Both studies are demonstrating an exemplary safety profile for QRX003 Quoin expect

GlobeNewswire 9 months ago

QNRX
-2.43%

Performance Overview

Return	QNRX	MSCI WORLD
YTD	-85.32%	+9.32%
1-Year	-86.01%	+22.52%
3-Year	-99.96%	+16.63%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Quoin Pharmaceuticals, Ltd. (QNRX)

QNRX: Protocol Modifications Potentially Accelerate, Expand QRX003 Approvals

Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2024 Financial Results

Quoin Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 9, 2024

Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Q4 2023 Earnings Call Transcript

Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results

Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ET

QNRX: Potential Pool of Study Participants Expands; Financial Position Strengths

Quoin Pharmaceuticals Announces Pricing of $6.5 Million Public Offering

Quoin Pharmaceuticals Announces FDA Clearance to Recruit Teen Subjects into Both Ongoing Netherton Syndrome Clinical Studies

Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Netherton Syndrome Combination Product

Quoin Pharmaceuticals Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton Syndrome

QNRX: Planned Protocol Modifications Might Accelerate QRX003 Regulatory Approval

Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Q3 2023 Earnings Call Transcript

Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2023 Financial Results

Quoin Pharmaceuticals Announces Third Quarter 2023 Financial Results and Corporate Update Conference Call to be held on Thursday November 9th at 8:30 am ET

REPEAT -- Quoin Pharmaceuticals Announces Additional Positive Clinical Data from Open-Label, Single-Arm Clinical Trial in Netherton Syndrome

Quoin Pharmaceuticals Announces Additional Positive Clinical Data from Open-Label, Single-Arm Clinical Trial in Netherton Syndrome

QNRX: Positive Early Clinical Data, Moving QRX003 Through Multiple Trials

Quoin Pharmaceuticals' Commitment to Delivering Treatment for Netherton Syndrome Patients and Creating Value for Shareholders

Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2023 Financial Results

Performance Overview